Text Size

Questionnaire and Laboratory Data on Vitiligo Vulgaris

This study is currently recruiting participants.
Verified July 2011 by St. Luke's-Roosevelt Hospital Center
Sponsor:
Collaborator:
Beth Israel Medical Center
Information provided by:
St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier:
NCT01206374
First received: September 20, 2010
Last updated: July 21, 2011
Last verified: July 2011
History of Changes
  Purpose

Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.


Condition
Vitiligo Vulgaris

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris

Resource links provided by NLM:

MedlinePlus related topics: Vitiligo
U.S. FDA Resources

Further study details as provided by St. Luke's-Roosevelt Hospital Center:

Estimated Enrollment: 300
Study Start Date: August 2010
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Detailed Description:

Patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

All patients willing to sign consent, complete questionnaire and/ or laboratory studies.

Criteria

Inclusion Criteria:

  • Diagnosis of Vitiligo Vulgaris
  • Ability to sign consent

Exclusion Criteria:

  • Pregnant
  • Inability to sign consent
  • Inability to complete questionnaire
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01206374

Contacts
Contact: Nanette B Silverberg, MD 212-523-3888 nsilverb@chpnet.org
Contact: Ingrid Sanabria 212-523-3888 isanabria@chpnet.org

Locations
United States, New York
Department of Dermatology, St. Luke's-Roosevelt Hospital Center Recruiting
New York, New York, United States, 10025
Contact: Ingrid Sanabria     212-523-3888     isanabria@chpnet.org    
Contact: Nanette Silverberg, MD     212-523-3888     nsilverb@chpnet.org    
Principal Investigator: Nanette Silverberg, MD            
Department of Dermatology, Beth Israel Medical Center Recruiting
New York, New York, United States, 10003
Contact: Ingrid Sanabria     212-523-3888     isanabria@chpnet.org    
Contact: Nanette Silverberg, MD     212-523-3888     nsilverb@chpnet.org    
Principal Investigator: Nanette Silverberg, MD            
Sponsors and Collaborators
St. Luke's-Roosevelt Hospital Center
Beth Israel Medical Center
Investigators
Principal Investigator: Nanette Silverberg, MD StLukesNY
  More Information

Publications:

Responsible Party: Nanette B. Silverberg, MD, Department of Dermatology, St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier: NCT01206374     History of Changes
Other Study ID Numbers: 10-027SLRHC
Study First Received: September 20, 2010
Last Updated: July 21, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by St. Luke's-Roosevelt Hospital Center:
Vitiligo Vulgaris

Additional relevant MeSH terms:
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases

ClinicalTrials.gov processed this record on June 18, 2013